Dosage and Research Laboratories - Pharmacy Technician Pulse

Search:

DAY

WEEK

MONTH

YEAR

Select your country:
Sign up | Log in

Dosage

Research Laboratories

First virtual clinical trial examines two promising Alzheimer’s drugs

European Pharmaceutical Review

NOVEMBER 4, 2022

A new computer model has successfully simulated a clinical trial evaluating the efficacy of aducanumab and donanemab for Alzheimer’s disease (AD), establishing a gradual increase in dosage up to the maximum dose helps to minimise cognitive decline and limit side effects. . We’ve shown that this type of model can work.

Research Laboratories

Research Laboratories Dosage FDA

Merck & Co plans to file cough drug gefapixant after phase 3 success

pharmaphorum

SEPTEMBER 9, 2020

Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, said: “COUGH-1 and COUGH-2 are the first companion Phase 3 trials in refractory or unexplained chronic cough, underscoring Merck’s commitment to fully researching the potential for gefapixant in this patient population.

Research Laboratories

Research Laboratories Dosage

First virtual clinical trial examines two promising Alzheimer’s drugs

Merck & Co plans to file cough drug gefapixant after phase 3 success

Stay Connected